YOLFTbeta
Universe Pharmaceuticals Inc

Universe Pharmaceuticals Inc

UPC · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

1.51USD-0.02 (-1.31%)

Price History

Full chart

Market Stats

Previous Close1.53
Open1.48
Day Range1.47 – 1.58
52-Week Range2.00 – 17.96
Volume13.05K
Market Cap23.87M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.38
Dividend Yield0.00%
Beta1.59
50-Day Avg4.82
200-Day Avg3.86

About

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Gang Lai
  • Employees216
  • Headquarters265 Jingjiu Avenue, Ji'An, China, 343100, USA
  • Websitehttps://www.universe-pharmacy.com

Leadership

  • Mr. Gang LaiCEO & Chairman · b. 1968
  • Ms. Lin YangCFO & Director · b. 1976
  • Mr. Baochang LiuChief Operating Officer · b. 1981

Financials

Income Statement

Currency: USD2018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue28.51M33.23M30.70M47.98M40.14M32.31M23.02M17.86M
Growth (%)-+16.54%-7.60%+56.27%-16.34%-19.52%-28.74%-22.44%
Cost of Revenue15.11M19.82M16.61M22.66M18.25M21.99M16.95M11.56M
Gross Profit13.41M13.41M14.09M25.33M21.89M10.32M6.07M6.30M
Gross Margin47.03%40.35%45.90%52.78%54.53%31.93%26.37%35.28%
Operating Expense3.75M3.65M3.84M11.74M28.91M13.84M14.09M9.22M
Operating Income9.66M9.75M10.25M13.59M-7.02M-3.53M-8.02M-2.92M
Operating Margin33.87%29.35%33.39%28.32%-17.49%-10.92%-34.83%-16.33%
EBITDA10.11M10.17M10.61M14.20M-6.40M-3.18M-7.36M-2.92M
EBITDA Margin35.47%30.62%34.56%29.59%-15.94%-9.85%-31.95%-16.37%
Net Income7.60M7.55M7.56M11.32M-8.74M-6.16M-8.73M-3.67M
Net Income Margin26.66%22.73%24.62%23.59%-21.76%-19.08%-37.90%-20.56%
R&D789.38K618.44K583.13K5.47M7.62M4.86M3.60M671.76K
R&D as % of Total Revenue2.77%1.86%1.90%11.39%18.99%15.04%15.63%3.76%
Interest Expense164.92K129.27K123.76K101.60K162.40K156.79K278.17K232.04K
Interest Expense % of Total Revenue0.58%0.39%0.40%0.21%0.40%0.49%1.21%1.30%

Balance Sheet

Currency: USD2018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets28.08M17.84M28.80M70.14M59.54M53.29M67.95M69.30M
Total Liabilities18.40M5.45M8.00M11.21M13.10M13.75M22.45M13.17M
Total Equity9.68M12.38M20.80M58.93M46.44M39.53M45.50M56.13M
Cash6.19M3.18M10.06M8.08M5.71M5.29M29.50M33.59M
Total Debt2.62M2.52M2.65M4.33M3.94M5.48M-9.26M
Net Debt-3.57M-655.52K-7.41M-3.74M-1.78M197.21K--24.34M

Cash Flow

Currency: USD2018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow4.46M13.20M6.12M-2.06M-1.31M1.12M-9.51M-5.05M
Investing Cash Flow-145.09K-86.03K-51.80K-27.06M-3.91M-44.17K--341.81K
Financing Cash Flow-4.91M-16.00M470.14K26.58M3.32M-1.39M33.95M9.73M
Capital Expenditure145.09K86.32K51.80K13.53M93.70K44.17K363.09K347.19K
Free Cash Flow4.31M13.12M6.06M-15.59M-1.41M1.08M-9.87M-5.40M
Dividends Paid3.06M16.00M000---
FCF to OCF96.74%99.35%99.15%758.18%107.14%96.06%103.82%106.87%
Dividend Paid to FCF70.99%122.01%0.00%0.00%0.00%---

Earnings

Report DateDec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Aug 17, 2020Dec 31, 2020Mar 24, 2021Aug 2, 2021Jan 31, 2022Aug 16, 2022Feb 10, 2023Sep 20, 2024Apr 29, 2025Jul 3, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual0.130.130.110.110.160.160.080.360.220.360.440.600.08-0.480.000.00-9.44
Surprise-----------------
Timing-----------------

Key Statistics & Ratios

Market Cap23.87M
Enterprise Value4.07M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.35
Price / Book0.42
EPS-1.38
Book Value98.78
Revenue (TTM)17.74M
Gross Profit (TTM)6.48M
EBITDA-1.61M
Profit Margin-10.95%
Operating Margin-16.60%
Return on Equity-3.51%
Return on Assets-1.72%
Shares Outstanding5.01M
Shares Float62.77K
Beta1.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.31%
Insiders
88.82%
Retail / Other
9.87%

Top Institutional Holders

  • UBS Group AG
    00.00%

Top Fund Holders

  • Cinvest Azero Global FI
    4.96K0.88%

Stock Splits

  • Mar 24, 20251:40
  • Nov 18, 20241:15